Latest News and Press Releases

HUDDINGE, Sweden, Sept. 10, 2002 (PRIMEZONE) -- Jonas Frick, CEO of Medivir since Stock Exchange listing in 1996, will leave the Company for a role as a Senior Partner of Scandinavian Life Science...

HUDDINGE, Sweden, July 8, 2002 (PRIMEZONE) -- Medivir: -- MIV-310 demonstrated powerful antiviral effect on patients with multiresistant HIV; these results, from a phase IIa trial, were ...

HUDDINGE, Sweden, May 31, 2002 (PRIMEZONE) -- A phase IIa clinical study with Medivir's compound MIV-310 shows a major antiviral effect in patients with multi drug resistant HIV. The addition of...

HUDDINGE, Sweden, May 29, 2002 (PRIMEZONE) -- Medivir and Peptimmune jointly announced today that, an orally active, small molecule inhibitor of the protease enzyme Cathepsin S, suppresses the...

HUDDINGE, Sweden, April 26, 2002 (PRIMEZONE) -- Medivir: - MIV-606 against shingles: US market rights outlicensed to Reliant Pharmaceuticals, raising a SEK 50 m up-front payment. Medivir...

HUDDINGE, Sweden, April 25, 2002 (PRIMEZONE) -- During its Q1 report telephone conference on April 24th Chiron announced that it has decided to stop the collaboration with Medivir on MIV-150...

HUDDINGE, Sweden, April 15, 2002 (PRIMEZONE) -- Medivir today announced that it has signed an agreement with Roche for the out-licensing of its innovative HIV treatment MV026048. MV026048 is a...

HUDDINGE, Sweden, Feb. 15, 2002 (PRIMEZONE) -- Medivir: -- MIV-606 against shingles: Outlicensing activities are in an intensive phase. -- In December, Medivir and Peptimmune announced a...